Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
Venetoclax for multiple myeloma - mechanism of action and next steps
Highlights on interesting data presented at COMy 2017
Selinexor for CLL - mechanism of action and combination with ibrutinib
What is the role for idelalisib and duvelisib in CLL?